Aduro Biotech Inc. (ADRO) Insider Thomas W. Dubensky Sells 25,000 Shares
Aduro Biotech Inc. (NASDAQ:ADRO) insider Thomas W. Dubensky sold 25,000 shares of Aduro Biotech stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $12.68, for a total transaction of $317,000.00. Following the completion of the transaction, the insider now owns 55,424 shares of the company’s stock, valued at approximately $702,776.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Aduro Biotech Inc. (NASDAQ:ADRO) opened at 13.64 on Thursday. The firm’s market capitalization is $883.24 million. The stock has a 50 day moving average of $14.13 and a 200-day moving average of $13.11. Aduro Biotech Inc. has a one year low of $7.26 and a one year high of $34.95.
Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.21. Aduro Biotech had a negative return on equity of 9.23% and a negative net margin of 23.69%. The firm had revenue of $39 million for the quarter, compared to analysts’ expectations of $25.24 million. The firm’s revenue for the quarter was up 306.3% compared to the same quarter last year. On average, equities analysts predict that Aduro Biotech Inc. will post ($1.39) EPS for the current year.
A number of institutional investors have recently made changes to their positions in the company. Alps Advisors Inc. boosted its position in shares of Aduro Biotech by 27.7% in the second quarter. Alps Advisors Inc. now owns 90,766 shares of the company’s stock valued at $1,027,000 after buying an additional 19,663 shares during the period. American Century Companies Inc. purchased a new position in shares of Aduro Biotech during the second quarter valued at about $1,265,000. Acadian Asset Management LLC boosted its position in shares of Aduro Biotech by 310.2% in the second quarter. Acadian Asset Management LLC now owns 221,028 shares of the company’s stock valued at $2,500,000 after buying an additional 167,140 shares during the period. Creative Planning purchased a new position in shares of Aduro Biotech during the second quarter valued at about $158,000. Finally, First Republic Investment Management Inc. purchased a new position in shares of Aduro Biotech during the first quarter valued at about $633,000. Hedge funds and other institutional investors own 29.76% of the company’s stock.
A number of research analysts recently issued reports on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $30.00 price target on shares of Aduro Biotech in a research note on Friday, August 5th. Zacks Investment Research cut shares of Aduro Biotech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Finally, Roth Capital reissued a “buy” rating and set a $22.00 price objective on shares of Aduro Biotech in a report on Monday, July 11th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $22.00.
Aduro Biotech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.